BCA
TPTX

Berman Capital Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Berman Capital Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$0 Buy
+12
New +$855 ﹤0.01% 2291
2021
Q2 		– Sell
-3
Closed – – 2100
2021
Q1 		$0 Hold
3
– – ﹤0.01% 1963
2020
Q4 		$0 Buy
+3
New +$329 ﹤0.01% 1887

Other funds holding TPTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Berman Capital Advisors's TPTX Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2021: 12 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2291 among its holdings. This is a return to the name: Berman Capital Advisors previously reported a position in TPTX as recently as Q1 2021.

Berman Capital Advisors first reported a position in TPTX in Q4 2020 and has held it in 3 quarters since. 190 funds tracked by Wall St. Rank hold TPTX as of Q3 2021.

  • Berman Capital Advisors held 12 shares of Turning Point Therapeutics, Inc. Common Stock worth $0 as of Q3 2021.
  • Turning Point Therapeutics, Inc. Common Stock was a new Berman Capital Advisors position in Q3 2021.
  • Turning Point Therapeutics, Inc. Common Stock made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2291 holding.
  • Berman Capital Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and has held it in 3 quarters since.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.